Smith & Nephew vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Smith & Nephew PLC (SN.LSE)

Q3 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

August 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Latest23 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.